X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs SANOFI INDIA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD SANOFI INDIA LUPIN LTD/
SANOFI INDIA
 
P/E (TTM) x 20.3 34.3 59.2% View Chart
P/BV x 2.8 6.5 42.1% View Chart
Dividend Yield % 0.9 1.4 65.9%  

Financials

 LUPIN LTD   SANOFI INDIA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
SANOFI INDIA
Dec-16
LUPIN LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,7504,560 38.4%   
Low Rs1,3844,400 31.4%   
Sales per share (Unadj.) Rs387.41,028.5 37.7%  
Earnings per share (Unadj.) Rs56.6129.0 43.9%  
Cash flow per share (Unadj.) Rs76.8186.0 41.3%  
Dividends per share (Unadj.) Rs7.5068.00 11.0%  
Dividend yield (eoy) %0.51.5 31.5%  
Book value per share (Unadj.) Rs298.9753.6 39.7%  
Shares outstanding (eoy) m451.5823.03 1,960.8%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.04.4 92.8%   
Avg P/E ratio x27.734.7 79.6%  
P/CF ratio (eoy) x20.424.1 84.6%  
Price / Book Value ratio x5.25.9 88.2%  
Dividend payout %13.252.7 25.1%   
Avg Mkt Cap Rs m707,513103,174 685.7%   
No. of employees `00016.83.6 463.5%   
Total wages/salary Rs m28,4953,592 793.3%   
Avg. sales/employee Rs Th10,418.36,537.7 159.4%   
Avg. wages/employee Rs Th1,697.0991.4 171.2%   
Avg. net profit/employee Rs Th1,523.0819.8 185.8%   
INCOME DATA
Net Sales Rs m174,94323,686 738.6%  
Other income Rs m1,065708 150.4%   
Total revenues Rs m176,00824,394 721.5%   
Gross profit Rs m44,9315,281 850.8%  
Depreciation Rs m9,1221,313 694.8%   
Interest Rs m1,52515 10,168.7%   
Profit before tax Rs m35,3494,661 758.4%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7851,691 578.7%   
Profit after tax Rs m25,5752,970 861.1%  
Gross profit margin %25.722.3 115.2%  
Effective tax rate %27.736.3 76.3%   
Net profit margin %14.612.5 116.6%  
BALANCE SHEET DATA
Current assets Rs m119,54215,673 762.7%   
Current liabilities Rs m61,2066,678 916.5%   
Net working cap to sales %33.338.0 87.8%  
Current ratio x2.02.3 83.2%  
Inventory Days Days7676 100.0%  
Debtors Days Days9022 402.7%  
Net fixed assets Rs m131,6608,098 1,625.8%   
Share capital Rs m903230 392.2%   
"Free" reserves Rs m134,07317,088 784.6%   
Net worth Rs m134,97617,356 777.7%   
Long term debt Rs m56,4780-   
Total assets Rs m266,07325,400 1,047.5%  
Interest coverage x24.2311.7 7.8%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.70.9 70.5%   
Return on assets %10.211.8 86.7%  
Return on equity %18.917.1 110.7%  
Return on capital %19.326.9 71.5%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m81,8857,145 1,146.0%   
Fx outflow Rs m21,5066,846 314.1%   
Net fx Rs m60,378299 20,193.4%   
CASH FLOW
From Operations Rs m41,1483,226 1,275.5%  
From Investments Rs m-25,287-1,555 1,626.2%  
From Financial Activity Rs m4,332-1,818 -238.3%  
Net Cashflow Rs m20,193-147 -13,736.4%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 60.4 0.3%  
Indian inst/Mut Fund % 11.3 14.4 78.5%  
FIIs % 31.9 14.6 218.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 15,184 647.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS